Niagen Bioscience (NAGE) Cash from Financing Activities (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Cash from Financing Activities of -$2.3 million for Q1 2026, down 173.75% year-over-year from $3.1 million in Q1 2025, and down 2762.5% quarter-over-quarter from -$80000.0 in Q4 2025.
Niagen Bioscience (NAGE) Cash from Financing Activities (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Cash from Financing Activities for 14 consecutive years, with -$2.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 173.75% year-over-year to -$2.3 million; the TTM figure through Mar 2026 stood at $1.5 million (down 82.08% YoY), while the FY2025 annual figure was $6.9 million, up 28.81% from the prior year.
- Cash from Financing Activities declined to -$2.3 million in Q1 2026 per NAGE's latest filing, from -$80000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $7.7 million in Q4 2022 and bottomed at -$2.3 million in Q1 2026.
- Historically, Cash from Financing Activities has averaged $1.0 million across 5 years, with a median of -$3000.0 in 2022.
- On a YoY basis, Cash from Financing Activities climbed as much as 34733.33% in 2024 and fell as far as 1300.0% in 2024.
- Niagen Bioscience's Cash from Financing Activities stood at $7.7 million in 2022, then slumped by 100.99% to -$76000.0 in 2023, then soared by 5031.58% to $3.7 million in 2024, then sank by 102.13% to -$80000.0 in 2025, then sank by 2762.5% to -$2.3 million in 2026.
- Business Quant data shows NAGE's Cash from Financing Activities at -$2.3 million in Q1 2026, -$80000.0 in Q4 2025, and $148000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | -2.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.49 Mn |
| Jun 30, 2026 | -2.49 Mn |
| Mar 31, 2026 | -2.29 Mn |
| Mar 31, 2026 | -2.29 Mn |
| Dec 31, 2025 | -80,000.00 |
| Dec 31, 2025 | -80,000.00 |
| Sep 30, 2025 | 148,000.00 |
| Sep 30, 2025 | 148,000.00 |
| Jun 30, 2025 | 3.74 Mn |
| Jun 30, 2025 | 3.74 Mn |
| Mar 31, 2025 | 3.11 Mn |
| Mar 31, 2025 | 3.11 Mn |
| Dec 31, 2024 | 3.75 Mn |
| Dec 31, 2024 | 3.75 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 596,000.00 |
| Jun 30, 2024 | 596,000.00 |
| Mar 31, 2024 | -14,000.00 |
| Mar 31, 2024 | -14,000.00 |